These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 20837981)

  • 1. Core ADHD symptom improvement with atomoxetine versus methylphenidate: a direct comparison meta-analysis.
    Hazell PL; Kohn MR; Dickson R; Walton RJ; Granger RE; Wyk GW
    J Atten Disord; 2011 Nov; 15(8):674-83. PubMed ID: 20837981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial.
    Wang Y; Zheng Y; Du Y; Song DH; Shin YJ; Cho SC; Kim BN; Ahn DH; Marquez-Caraveo ME; Gao H; Williams DW; Levine LR
    Aust N Z J Psychiatry; 2007 Mar; 41(3):222-30. PubMed ID: 17464703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial.
    Kratochvil CJ; Heiligenstein JH; Dittmann R; Spencer TJ; Biederman J; Wernicke J; Newcorn JH; Casat C; Milton D; Michelson D
    J Am Acad Child Adolesc Psychiatry; 2002 Jul; 41(7):776-84. PubMed ID: 12108801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
    Niederkirchner K; Slawik L; Wermelskirchen D; Rettig K; Schäuble B
    Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atomoxetine. Attention-deficit/hyperactivity disorder: no better than methylphenidate.
    Prescrire Int; 2010 Feb; 19(105):5-8. PubMed ID: 20455329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder.
    Schulz KP; Fan J; Bédard AC; Clerkin SM; Ivanov I; Tang CY; Halperin JM; Newcorn JH
    Arch Gen Psychiatry; 2012 Sep; 69(9):952-61. PubMed ID: 22945622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit/Hyperactivity Disorder.
    Shang CY; Pan YL; Lin HY; Huang LW; Gau SS
    J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):566-73. PubMed ID: 26222447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of symptomatic versus functional changes in children and adolescents with ADHD during randomized, double-blind treatment with psychostimulants, atomoxetine, or placebo.
    Buitelaar JK; Wilens TE; Zhang S; Ning Y; Feldman PD
    J Child Psychol Psychiatry; 2009 Mar; 50(3):335-42. PubMed ID: 19309330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How oppositionality, inattention, and hyperactivity affect response to atomoxetine versus methylphenidate: a pooled meta-analysis.
    van Wyk GW; Hazell PL; Kohn MR; Granger RE; Walton RJ
    J Atten Disord; 2012 May; 16(4):314-24. PubMed ID: 21289234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.
    Gibson AP; Bettinger TL; Patel NC; Crismon ML
    Ann Pharmacother; 2006 Jun; 40(6):1134-42. PubMed ID: 16735655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis.
    Hanwella R; Senanayake M; de Silva V
    BMC Psychiatry; 2011 Nov; 11():176. PubMed ID: 22074258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine.
    Roskell NS; Setyawan J; Zimovetz EA; Hodgkins P
    Curr Med Res Opin; 2014 Aug; 30(8):1673-85. PubMed ID: 24627974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of atomoxetine in children with severe autistic disorders and symptoms of ADHD: an open-label study.
    Charnsil C
    J Atten Disord; 2011 Nov; 15(8):684-9. PubMed ID: 20686100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of parent and teacher reports of attention-deficit/hyperactivity disorder symptoms from two placebo-controlled studies of atomoxetine in children.
    Biederman J; Gao H; Rogers AK; Spencer TJ
    Biol Psychiatry; 2006 Nov; 60(10):1106-10. PubMed ID: 16806096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naïve children and adolescents with attention deficit/hyperactivity disorder.
    Montoya A; Hervas A; Cardo E; Artigas J; Mardomingo MJ; Alda JA; Gastaminza X; García-Polavieja MJ; Gilaberte I; Escobar R
    Curr Med Res Opin; 2009 Nov; 25(11):2745-54. PubMed ID: 19785510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder.
    Biederman J; Wigal SB; Spencer TJ; McGough JJ; Mays DA
    Clin Ther; 2006 Feb; 28(2):280-93. PubMed ID: 16678649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response.
    Newcorn JH; Kratochvil CJ; Allen AJ; Casat CD; Ruff DD; Moore RJ; Michelson D;
    Am J Psychiatry; 2008 Jun; 165(6):721-30. PubMed ID: 18281409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life and attention-deficit/hyperactivity disorder core symptoms: a pooled analysis of 5 non-US atomoxetine clinical trials.
    Escobar R; Schacht A; Wehmeier PM; Wagner T
    J Clin Psychopharmacol; 2010 Apr; 30(2):145-51. PubMed ID: 20520287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD).
    Prasad S; Harpin V; Poole L; Zeitlin H; Jamdar S; Puvanendran K;
    Curr Med Res Opin; 2007 Feb; 23(2):379-94. PubMed ID: 17288692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.